SCHOLAR ROCK HOLDING CORPORATION
Scholar Rock Holding Corp (SRRK) is a clinicalβstage biopharmaceutical company focused on developing therapies that modulate the transforming growth factorβbeta (TGFβΞ²) signalling pathway. The companyβs pipeline targets conditions where TGFβΞ² is implicated, with several clinical programmes progressing through trials. As a specialist biotech, Scholar Rockβs value is shaped heavily by clinical results, regulatory decisions and partnerships rather than current product revenues. With a market capitalisation around $2.7 billion, the stock can offer exposure to potential upside from successful trials but also carries typical biotech risks: trial setbacks, regulatory hurdles and cash burn needing future financing. Investors should consider time horizon, risk tolerance and the binary nature of clinical catalysts. This summary is for educational purposes only and is not personalised investment advice; investors should conduct further research or consult an authorised financial adviser before acting.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Scholar Rock's stock, expecting it to rise towards a higher target price.
Financial Health
Scholar Rock is demonstrating solid cash flow and a reasonable book value, indicating good financial stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ARCELLX INC
Develops T-cell therapies for the treatment of cancer.
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring SRRK
Gene Therapy's Competitive Shift
The European Medicines Agency's recent rejection of Sarepta Therapeutics' gene therapy creates a potential opening for its competitors. This theme focuses on the biopharmaceutical companies that stand to benefit from this regulatory hurdle in the Duchenne muscular dystrophy market.
Published: July 25, 2025
Explore BasketWhy Youβll Want to Watch This Stock
Clinical-stage drug focus
The companyβs value hinges on clinical readouts and scientific validation, which can create material shareβprice moves; outcomes are uncertain.
Pipeline catalysts ahead
Upcoming trial milestones and partnerships can drive momentum, though any positive prospects may be offset by trial or regulatory disappointment.
Regulatory and cashflow
Regulatory approvals and financing decisions will shape longβterm prospects; investors should watch cash runway and funding plans carefully.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
